What makes Retatrutide unique is that it targets THREE receptors.
Semaglutide targeted the receptor glucagon-like peptide-1 (GLP-1), and Tirzepatide targeted both the GLP-1 receptor and glucose-dependent insulinotropic peptide (GIP) receptor.
This potentially all-powerful weight loss drug tackles GLP-1 and GIP receptors while also targeting the body’s glucagon receptors.
Supposedly, what this does is give the drug a DIRECT effect on energy expenditure (unlike its predecessors).
We effectively have a lowering of appetite from GLP-1, improved fat clearance and stimulate the release of lipoprotein lipase from fat with GIP, and a higher metabolic rate with the glucagon receptor.
Take a look at this early preclinical study done in mice and tell me your mind isn’t BLOWN AWAY:
Tirzepatide is in blue and Retatrutide is in red — not only is the total weight loss significantly larger, but the majority of weight loss is pure fat.
www.ncbi.nlm.nih.gov
Semaglutide targeted the receptor glucagon-like peptide-1 (GLP-1), and Tirzepatide targeted both the GLP-1 receptor and glucose-dependent insulinotropic peptide (GIP) receptor.
This potentially all-powerful weight loss drug tackles GLP-1 and GIP receptors while also targeting the body’s glucagon receptors.
Supposedly, what this does is give the drug a DIRECT effect on energy expenditure (unlike its predecessors).
We effectively have a lowering of appetite from GLP-1, improved fat clearance and stimulate the release of lipoprotein lipase from fat with GIP, and a higher metabolic rate with the glucagon receptor.
Take a look at this early preclinical study done in mice and tell me your mind isn’t BLOWN AWAY:
Tirzepatide is in blue and Retatrutide is in red — not only is the total weight loss significantly larger, but the majority of weight loss is pure fat.
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic ...
www.ncbi.nlm.nih.gov
